MedTrace Logo

Comparison of HT Concomitant With RT vs RT Alone in Patients With a Detectable PSA After Prostatectomy

NCT01994239 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 120

Last updated 2024-12-16

No results posted yet for this study

Summary

The purpose of this study is to select the best therapeutic strategy in studying the effectiveness of the association of a short duration hormonal therapy and radiotherapy compared with radiotherapy alone, in patients with a detectable PSA after radical prostatectomy.

Conditions

  • Adenocarcinoma of Prostate

Interventions

DRUG

Degarelix

First dose of 240 mg 5 Maintenance doses of 80 mg every 28 days(+/-3d)

RADIATION

Pelvic Radiotherapy

46 Gy in 23 fractions Prostate only-boost up to 66 Gy

Sponsors & Collaborators

  • Ferring Pharmaceuticals

    collaborator INDUSTRY

  • UNICANCER

    lead OTHER

Principal Investigators

  • Igor LATORZEFF · Clinique Pasteur

  • Laurent SALOMON · CHU Henri Mondor

  • Paul SARGOS · Institut Bergonié

  • Emmanuel MEYER · Centre François Baclesse

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-12-31
Primary Completion
2022-03-31
Completion
2025-03-31

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01994239 on ClinicalTrials.gov